Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to ...

Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression, Cancer Cell, June 2025 DOI: (25)00253-3 ...

Low-grade serous ovarian cancer (LGSC), accounts for just 5% to 10% of all epithelial ovarian cancers, but its distinct biology makes it especially challenging to treat. While the origin of this ...

Non-invasive epithelial tumors of the ovary that show abnormal cell growth but lack the capacity to invade surrounding ...

An interdisciplinary study uncovers how benign borderline ovarian tumors develop into invasive low-grade serous carcinoma, ...

A new technique lets researchers make many more of the particles much faster, using consistent practices that meet safety ...

CAR-T therapy targeting TM4SF1 in aggressive bladder cancer (HV) histologic variant , offering hope for treatment-resistant ...

Dubai, United Arab Emirates — Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, may be key in helping the immune system fight tumors in ovarian cancer. The study, ...

As immunotherapy becomes a cornerstone of cancer treatment, some of the top U.S. cancer centers and health systems are accelerating research efforts to identify the biological mechanisms behind ...

A diagnosis of 4 stage ovarian cancer can be devastating. However, advances in medical science are helping patients and offering them hope ...